Market Newsdesk

AVROBIO to Present at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit

CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Azadeh Golipour, VP of Manufacturing Operations at AVROBIO, will present virtually at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit at 11:30 a.m. ET on Friday, Jan. 29, 2021.

About AVROBIO

Our vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone. Our ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease. AVROBIO is powered by our industry leading plato^® gene therapy platform, our foundation designed to deliver gene therapy worldwide. We are headquartered in Cambridge, Mass., with an office in Toronto, Ontario. For additional information, visit avrobio.com, and follow us on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “aims,” “anticipates,” “believes,” “could,” “designed to,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words and phrases or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding our business strategy for and the potential therapeutic benefits of our product candidates, the design, commencement, enrollment and timing of ongoing or planned clinical trials, clinical trial results, product approvals and regulatory pathways, and anticipated benefits of our gene therapy platform including potential impact on our commercialization activities, timing and likelihood of success.

Any forward-looking statements in this press release are based on AVROBIO’s current expectations, estimates and projections about our industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of AVROBIO’s product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned preclinical or clinical trials of AVROBIO or our collaborators, the risk that AVROBIO may not successfully recruit or enroll a sufficient number of patients for our clinical trials, the risk that AVROBIO may not realize the intended benefits of our gene therapy platform, including the features of our plato platform, the risk that our product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate, the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or trials involving AVROBIO’s product candidates, the risk that we will be unable to obtain and maintain regulatory approval for our product candidates, the risk that the size and growth potential of the market for our product candidates will not materialize as expected, risks associated with our dependence on third-party suppliers and manufacturers, risks regarding the accuracy of our estimates of expenses and future revenue, risks relating to our capital requirements and needs for additional financing, risks relating to clinical trial and business interruptions resulting from the COVID-19 outbreak or similar public health crises, including that such interruptions may materially delay our development timeline and/or increase our development costs or that data collection efforts may be impaired or otherwise impacted by such crises, and risks relating to our ability to obtain and maintain intellectual property protection for our product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause AVROBIO’s actual results to differ materially and adversely from those contained in the forward-looking statements, see the section entitled “Risk Factors” in AVROBIO’s most recent Quarterly Report, as well as discussions of potential risks, uncertainties and other important factors in AVROBIO’s subsequent filings with the Securities and Exchange Commission. AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210122005062/en/

Investors:

Christopher F. Brinzey

Westwicke, an ICR Company

339-970-2843

[email protected]

Media:

Stephanie Simon

Ten Bridge Communications

617-581-9333

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Health Genetics Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Logo

Humanigen Announces the Addition of BARDA and Expansion of CRADA with the U.S. Government to Develop Lenzilumab for COVID-19

• The Cooperative Research and Development Agreement (CRADA) with the Department of Defense (DoD) and the Biomedical Advanced Research and Development Authority (BARDA) supports the development of lenzilumab as a potential treatment for patients with COVID-19

BURLINGAME, Calif.–(BUSINESS WIRE)–Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, today announced an expansion to the Cooperative Research and Development Agreement (CRADA) that the company had previously entered into with the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), to gain access to manufacturing capacity reserved by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services. The agreement supports development of lenzilumab in advance of a potential Emergency Use Authorization (EUA) for COVID-19.

The amended CRADA, now co-signed by BARDA, provides Humanigen with access to manufacturing capacity reserved by BARDA for fill-finish product to accelerate the drug product manufacturing of lenzilumab. The initial agreement, originally signed in November 2020, complements Humanigen’s development efforts for lenzilumab by providing access to a full-scale, integrated team of manufacturing and regulatory subject matter experts and statistical support in anticipation of applying for EUA and subsequently a Biologics License Application (BLA) for lenzilumab as a potential treatment for COVID-19. Lenzilumab is currently in a Phase 3 clinical trial evaluating patients hospitalized with COVID-19.

“It has been an honor to have the integrated expert team at BARDA prioritize lenzilumab research and development during this critical time,” said Cameron Durrant, MD, MBA, chief executive officer of Humanigen. “As we move closer to filing a potential EUA, the integrated support of BARDA and JPEO helps us with manufacturing capabilities as we ready operations to support access to lenzilumab.”

Humanigen’s investigational treatment lenzilumab, a proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, is designed to prevent and treat an immune hyper-response called cytokine storm, a complication considered to be a leading cause of COVID-19 death. Data showed that up to 89 percent of hospitalized patients with COVID-19 are at risk of this immune hyper-response, which is believed to trigger the acute respiratory distress syndrome in severe cases of COVID-19.

More details on Humanigen’s programs in COVID-19 can be found on the company’s website under the COVID-19 tab. Details on the U.S. Phase 3 lenzilumab clinical trial can be found at clinicaltrials.gov using Identifier NCT04351152. Details on ACTIV-5/BET can be found at clinicaltrials.gov using Identifier NCT04583969.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. Humanigen believes that its GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. Humanigen’s immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. Humanigen is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, Humanigen is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. Humanigen is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit www.humanigen.com and follow Humanigen on LinkedIn, Twitter and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although Humanigen management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as “will,” “expect,” “intend,” “plan,” “potential,” “possible,” “goals,” “accelerate,” “continue,” and similar expressions identify forward-looking statements, including, without limitation, statements regarding the use of lenzilumab to treat patients hospitalized with COVID-19, Humanigen’s expectations regarding the timeline to file for and obtain EUA, as well as a potential BLA filing, statements regarding Humanigen’s ability to attain necessary manufacturing support, and statements regarding Humanigen’s beliefs relating to any of the other technologies in Humanigen’s current pipeline. These forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in Humanigen’s lack of profitability and need for additional capital to grow Humanigen’s business; Humanigen’s dependence on partners to further the development of Humanigen’s product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory approvals or authorization for emergency or broader patient use for the product candidate and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the “Risk Factors” sections and elsewhere in the Humanigen’s periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. Humanigen undertakes no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210122005079/en/

Humanigen:

Investors:

Alan Lada

Solebury Trout

[email protected]

856-313-8206

Media:

Cammy Duong

Westwicke, an ICR company

[email protected]

203-682-8380

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Science Other Science Biotechnology Research Pharmaceutical Health Infectious Diseases Clinical Trials

MEDIA:

Logo

Housing Market Potential Expected to Build on Momentum in 2021, According to First American Potential Home Sales Model

—Twin housing market accelerants, record low mortgage rates and the demographic boost from millennials aging into their prime homebuying years, super-charged demand, says Chief Economist Mark Fleming—

SANTA ANA, Calif.–(BUSINESS WIRE)–First American Financial Corporation (NYSE: FAF), a leading global provider of title insurance, settlement services and risk solutions for real estate transactions, today released First American’s proprietary Potential Home Sales Model for the month of December 2020.

December 2020 Potential Home Sales

• Potential existing-home sales increased to a 6.18 million seasonally adjusted annualized rate (SAAR), a 2.3 percent month-over-month increase.
• This represents a 77.1 percent increase from the market potential low point reached in February 1993.
• The market potential for existing-home sales increased 11.9 percent compared with a year ago, a gain of nearly 658,628 (SAAR) sales.
• Currently, potential existing-home sales is 683,971 million (SAAR), or 10.0 percent below the pre-recession peak of market potential, which occurred in April 2006.

Market Performance Gap

• The market for existing-home sales underperformed its potential by 1.2 percent or an estimated 73,142 (SAAR) sales.
• The market performance gap increased by an estimated 21,960 (SAAR) sales between November 2020 and December 2020.

Chief Economist Analysis: Housing Market Potential Reached Highest Point Since 2007

“In the final month of 2020, the market potential for existing-home sales reached its highest point since 2007, rising to a 6.18 million seasonally adjusted annualized rate (SAAR) of sales,” said Mark Fleming, chief economist at First American. “While the winter months are traditionally real estate’s slow season, the housing market had one more surprise for us in 2020, as our measure of the market potential for existing-home sales showed the housing market again broke with traditional seasonal patterns during this unprecedented year.

“Twin housing market accelerants — record low mortgage rates and the demographic boost from millennials, the largest generation in U.S. history, aging into their prime homebuying years – super-charged demand. Yet, the housing market also faces a historic and worsening inventory impasse – you can’t buy what’s not for sale,” said Fleming. “In 2020, the growth in house-buying power fueled by low mortgage rates was the primary driver of housing market potential, while existing homeowners choosing not to list their homes for sale was the biggest headwind. Fortunately, the potential sales increase from house-buying power was more than the loss from rising tenure length in 2020.”

House-Buying Power, Millennials Super-Charge Housing Market Demand

“House-buying power, how much home one can afford to buy given their income and the prevailing mortgage rate, is a key driver of home-buying demand. The primary reason for the increase in house-buying power in 2020 was falling mortgage rates. Since December 2019, the 30-year, fixed-rate mortgage fell by slightly more than one percentage point. Holding household income constant at its December 2019 level, that means potential home buyers gained nearly $60,000 in house-buying power from falling mortgage rates alone,” said Fleming. “If you factor in the growth in household income, home buyers gained approximately $87,000 of total house-buying power in 2020. Because an increase in house-buying power allows a potential home buyer to purchase more home for the same monthly payment or purchase the same amount of home for a lower monthly payment, increased house-buying power helped super-charge housing market potential. Compared with one year ago, falling mortgage rates and rising incomes for those still employed resulted in nearly 389,000 potential home sales in December.”

Rising Tenure Squeezes Housing Market Supply

“Existing-home sales make up approximately 90 percent of all sales, so the rising tenure length of existing homeowners means fewer and fewer homes for sale and is the primary reason for the lack of housing supply. As existing homeowners have increasingly chosen not to list their homes for sale during the pandemic, average tenure length – the amount of time someone lives in their home – has soared to a historic high of approximately 10.5 years, up from an average of 10 years just one year ago,” said Fleming. “In last month’s existing-home sales report, months’ supply hit a historic low of 2.3 months. That means it would take just over two months to run out of homes for sale at the current pace of sales. The lack of homes for sale caused by the increase in tenure length reduced the potential for existing-home sales by 170,200 in December compared with a year ago.

“What should we expect in 2021? More of the same, but in a more positive economic environment. The successful dissemination of a vaccine should put an end to the ‘stop-start’ pattern of restrictions imposed on businesses, which should help the economy recover. Low mortgage rates will continue to support strong house-buying power as more and more millennials age into homeownership, keeping demand robust,” said Fleming. “While the supply-demand imbalance will persist, existing homeowners who were hesitant to sell amidst the worst of the pandemic may be encouraged to bring their homes to market, relieving some of the supply shortage. Swelling demand and the potential for greater supply means housing market potential in 2021 is likely to remain strong and build off a historic 2020.”

Next Release

The next Potential Home Sales Model will be released on February 18, 2021 with January 2021 data.

About the Potential Home Sales Model

Potential home sales measures existing-homes sales, which include single-family homes, townhomes, condominiums and co-ops on a seasonally adjusted annualized rate based on the historical relationship between existing-home sales and U.S. population demographic data, homeowner tenure, house-buying power in the U.S. economy, price trends in the U.S. housing market, and conditions in the financial market. When the actual level of existing-home sales are significantly above potential home sales, the pace of turnover is not supported by market fundamentals and there is an increased likelihood of a market correction. Conversely, seasonally adjusted, annualized rates of actual existing-home sales below the level of potential existing-home sales indicate market turnover is underperforming the rate fundamentally supported by the current conditions. Actual seasonally adjusted annualized existing-home sales may exceed or fall short of the potential rate of sales for a variety of reasons, including non-traditional market conditions, policy constraints and market participant behavior. Recent potential home sale estimates are subject to revision to reflect the most up-to-date information available on the economy, housing market and financial conditions. The Potential Home Sales model is published prior to the National Association of Realtors’ Existing-Home Sales report each month.

Disclaimer

Opinions, estimates, forecasts and other views contained in this page are those of First American’s Chief Economist, do not necessarily represent the views of First American or its management, should not be construed as indicating First American’s business prospects or expected results, and are subject to change without notice. Although the First American Economics team attempts to provide reliable, useful information, it does not guarantee that the information is accurate, current or suitable for any particular purpose. © 2021 by First American. Information from this page may be used with proper attribution.

About First American

First American Financial Corporation (NYSE: FAF) is a leading provider of title insurance, settlement services and risk solutions for real estate transactions that traces its heritage back to 1889. First American also provides title plant management services; title and other real property records and images; valuation products and services; home warranty products; property and casualty insurance; banking, trust and wealth management services; and other related products and services. With total revenue of $6.2 billion in 2019, the company offers its products and services directly and through its agents throughout the United States and abroad. In 2020, First American was named to the Fortune 100 Best Companies to Work For^® list for the fifth consecutive year. More information about the company can be found at www.firstam.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210122005026/en/

Media Contact:

Marcus Ginnaty

Corporate Communications

First American Financial Corporation

(714) 250-3298

Investor Contact:

Craig Barberio

Investor Relations

First American Financial Corporation

(714) 250-5214

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Commercial Building & Real Estate Insurance Construction & Property Finance Banking REIT Professional Services Other Construction & Property Residential Building & Real Estate

MEDIA:

Logo

Spectrum Pharmaceuticals Announces Two Oral Presentations at Upcoming IASLC 2020 World Conference on Lung Cancer

HENDERSON, Nev.–(BUSINESS WIRE)–
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on updated efficacy, safety, and dosing management of poziotinib from Cohorts 1 and 2 of the ZENITH20 clinical trial. In addition, Spectrum also announced an oral presentation on the structural classification of atypical EGFR mutations and their patterns of drug sensitivity. These presentations will take place as part of the IASLC 2020 World Conference on Lung Cancer (#WCLC20) hosted by the International Association for the Study of Lung Cancer (IASLC) taking place virtually January 28-31, 2021. Details of the presentations are as follows:

Title: Updated efficacy, safety, and dosing management of poziotinib in previously treated EGFR and HER2 exon 20 NSCLC patients

Speaker: Robin Cornelissen, Ph.D., M.D.

Session: Expanding Targetable Genetic Alterations in NSCLC Mini Oral Session

Date and Time: January 31, 2021, 14:20 SGT (January 30, 2021 10:20 p.m. PT)

Presentation Number: MA11.04

Title: Structural classification of atypical EGFR mutations identifies four major subgroups with distinct patterns of drug sensitivity

Speaker: Jacqulyne P. Robichaux. Ph.D.

Session: Tumor Biology: Focus on EGFR Mutation, DNA Repair and Tumor Microenvironment Mini Oral Session

Date and Time: January 31, 2021, 17:20 SGT (January 31, 2021 1:20 a.m. PT)

Presentation Number: MA13.07

Access to the presentations is available to members of IASLC and can be found here: https://wclc2020.iaslc.org/registration/.

AboutSpectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals please visit www.sppirx.com.

Forward-looking statement — This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management’s current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum’s business and its future, including certain company milestones, Spectrum’s ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrum’s existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the company’s reports filed with the Securities and Exchange Commission. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC.^® is a registered trademark of Spectrum Pharmaceuticals, Inc and its affiliate. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

© 2021 Spectrum Pharmaceuticals, Inc. All Rights Reserved

View source version on businesswire.com: https://www.businesswire.com/news/home/20210122005023/en/

Robert Uhl

Managing Director, Westwicke ICR

858.356.5932

[email protected]

Kurt Gustafson

Chief Financial Officer

949.788.6700

[email protected]

KEYWORDS: Nevada United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Logo

iHeartMedia Celebrates Third Annual iHeartRadio Podcast Awards

Will Ferrell makes his return to the iHeartRadio Podcast Awards with hilarious opening

Obama’s Other Daughters and hosts of “Las Culturistas” keep viewers laughing out loud all night with original comedy skits

“Office Ladies” takes home highly coveted “Podcast of the Year” award

Gwen Stefani presents the all-new “Seneca Women Podcast Award in partnership with P&G” to Amena Brown, which honors a woman who is using her voice to amplify the voices of other women

NEW YORK–(BUSINESS WIRE)–
Last night, the third annual iHeartRadio Podcast Awards brought together the most influential names in podcasting to honor the most entertaining and innovative podcasts of 2020, celebrating the incredible talent and wide variety of leaders across the booming podcasting industry. The virtual awards event was recorded from multiple locations and exclusively video streamed on iHeartRadio’s YouTube and Facebook pages and broadcasted across iHeartMedia radio stations nationwide and on the iHeartRadio App.

The virtual event kicked off with a hilarious opening from renowned actor, comedian and producer, Will Ferrell. The comedian, who is behind iHeartRadio’s “The Ron Burgundy Podcast,” broke the ice in true Ron Burgundy form, making up his own stats on both the awards show and podcasts. The upbeat tone of the virtual event continued throughout the night with comedic skits from the ladies of Obama’s Other Daughters, made up of Maame-Yaa Aforo, Ashley Holston, Shakira Ja’nai Paye and Yazmin Monet Watkins, hosts of “You Down?” as well as Bowen Yang and Matt Rogers, hosts of “Las Culturistas.”

The eventful night also featured appearances by award nominees, an array of celebrity presenters and other special guests including Aaron Mahnke, Adam Devine, Anders Holm, Baratunde Thurston, Blake Anderson, Charlamagne Tha God, Dan Patrick, Gwen Stefani, Hillary Clinton, Holly Frey, Jill Scott, Josh Clark and Chuck Bryant, Kyle Newacheck, Laverne Cox, Nikki Glaser, Questlove, Roy Wood Jr., Tenderfoot TV (Donald Albright and Payne Lindsey) and more.

The 2021 iHeartRadio Podcast Awards event highlights include:

• “Office Ladies” scored the big win of the night with Podcast of the Year, a socially voted category.

• GwenStefani presented the first Seneca Women Podcast Awardin partnership with P&G to spoken word poet AmenaBrown of “HER with Amena Brown.” This award honors women who use their voices to amplify those of other women.

• Hosts of “Las Culturistas” kickstarted the show reflecting on the year 2020 and podcasting, hilariously sharing that the best part about podcasting now is that you can do it naked and from home.

• Obama’s Other Daughters reminisced throughout the show on the top viral moments in awards show history and even attempted to do a virtual four-way kiss, inspired by Britney Spears, Madonna and Christina Aguilera’s three-way kiss at the MTV Video Music Awards.

• Hilary Clinton warm-heartedly presented the Icon Audible Pioneer Award to Neil Drumming, Sarah Koenig and Julie Snyder from Serial Productions.

• The iHeartRadio Podcast Awards honored Baratunde Thurston with the Icon Social Impact Award (presented by Questlove)and QCODE with the Icon Innovator Award (presented by Tenderfoot TV co-founders Donald Albright and Payne Lindsey).

• ConanO’Brien accepted the award for Best Overall Host–Male. He playfully told viewers that what separates his podcast from others is his “lack of professionalism.” He even shared his advice for those interested in hosting a podcast and more.

• Laverne Cox presented the Best Overall Host – Female award to Nicole Byer, host of “Why Won’t You Date Me.” While presenting the award, Cox inspired viewers, telling the virtual audience that everyone should have the opportunity to define who they are on their own terms. She also spoke about her first podcast launching in February 2021.

• DanPatrick presented the winner of The Next Great Podcast award, a months-long competition from iHeartRadio in partnership with content creation platform Tongal. Siena Jeakle and LiannaHolston won the competition with “Frankly, My Dear,” a new podcast tackling movie reviews from two friends who don’t really like movies.

Full list of category winners below:

Podcast of the Year:

● “Office Ladies” (Earwolf, Jenna Fischer, Angela Kinsey)

Icon Award – Innovator Award

● QCODE

Icon Award – Audible Audio Pioneer Award:

● Serial Productions (Sarah Koenig, Julie Snyder and Neil Drumming)

Icon Award – Social Impact Award:

● Baratunde Thurston

Best Crime Podcast:

● “Crime Junkie” (AudioChuck)

Best Pop Culture Podcast:

● “Pop Culture Happy Hour” (NPR)

Best Music Podcast:

● “Dolly Parton’s America” (WNYC & OSM Audio)

Best News Podcast:

● “Pod Save America” (Crooked)

Best Sports Podcast:

● “All The Smoke” (The Black Effect Podcast Network)

Best Comedy Podcast:

● “The Read” (Loud Speakers Network)

Best Political Podcast:

● “NPR Politics” (NPR)

Best Branded Podcast:

● “Humans Growing Stuff” (ScottsMiracle-Gro)

Best Kids & Family Podcast:

● “Wow In The World” (NPR)

Best Food Podcast:

● “Home Cooking” (Samin Nosrat / Hrishikesh Hirway )

Best Fiction Podcast:

● “Blood Ties” (Wondery)

Best Beauty & Fashion Podcast:

● “Articles of Interest” (Avery Trufelman / 99% Invisible)

Best Overall Host – Female:

● Nicole Byer (“Why Don’t You Date Me?”)

Best Overall Host – Male:

● Conan O’Brien (“Conan O’Brien Needs A Friend”)

Best Business & Finance Podcast:

● “Pivot” (NY Mag)

Best Green Podcast:

● “How To Save A Planet” (Gimlet)

Best Travel Podcast:

● “Travel with Rick Steves” (Rick Steves)

Best Spirituality & Religion Podcast:

● “Elevation with Steven Furtick” (Independent)

Best Advice / Inspirational Podcast:

● “Unlocking Us with Brene Brown” (Parcast)

Best TV & Film Podcast:

● “You Must Remember This?” (Karina Longworth)

Best Spanish-Language Podcast:

● “Leyendas Legendarias” (Sonoro / All Things Comedy)

Best Ad Read Podcast:

● “Office Ladies” (Earwolf / Stitcher)

Best Science Podcast:

● “Radiolab” (WNYC Studios)

Best Technology Podcast:

● “Rabbit Hole” (The New York Times)

Best Wellness & Fitness Podcast:

● “Therapy For Black Girls” (Joy Harden Bradford / iHeartRadio)

Best History Podcast:

● “Revisionist History” (Pushkin Industries)

The 2021 iHeartRadio Podcast Awards is part of iHeartMedia’s roster of incredibly successful, nationally-recognized events, including the iHeartRadio Music Awards, the iHeartRadio Music Festival, the nationwide iHeartRadio Jingle Ball Concert Tour, iHeartRadio Fiesta Latina, iHeartCountry Festival, iHeartRadio ALTer Ego and iHeartRadio Wango Tango. Executive producers for the iHeartRadio Podcast Awards are John Sykes, Tom Poleman and Conal Byrne for iHeartMedia and Deviants Media Studio founders Ivan Dudynsky and Buzz Chatman. Proud sponsors of this year’s event include Audible, P&G and Progressive® Insurance.More information can be found at iHeartPodcastAwards.com.

To access photos from the virtual event please visit:

https://iheartradio.photoshelter.com/galleries/C0000ZHDCxVqJsH4/G0000MrzMltNWYj0/Show

Password: iHRPodcast2021!

Photo Credit: iHeartRadio

To access b-roll from this virtual event please visit:

https://crazyduck.wetransfer.com/downloads/0ce98b499c778868a00e8f5ea34d64f020210121094342/fb481c87bb4cb988d6941e0b5489dff220210121094342/a9b0e1

About iHeartMedia

iHeartMedia (NASDAQ: IHRT) is the number one audio company in the United States, reaching nine out of 10 Americans every month – and with its quarter of a billion monthly listeners, has a greater reach than any other media company in the U.S. The company’s leadership position in audio extends across multiple platforms, including more than 850 live broadcast stations in over 160 markets nationwide; through its iHeartRadio digital service available across more than 250 platforms and 2,000 devices; through its influencers; social; branded iconic live music events; other digital products and newsletters; and podcasts as the #1 commercial podcast publisher. iHeartMedia also leads the audio industry in analytics, targeting and attribution for its marketing partners with its SmartAudio product, using data from its massive consumer base. Visit iHeartMedia.com for more company information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210122005085/en/

iHeartMedia

Angel Aristone

[email protected]

347-380-2271

iHeartMedia

Jenn Powers

[email protected]

718-909-4767

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Entertainment General Entertainment TV and Radio Celebrity Online Events/Concerts

MEDIA:

Posted on January 22, 2021 7:03 am

Enthusiast Gaming Set to Strengthen Balance Sheet by $50 Million

Combination of recently announced bought deal equity financing and early conversion of convertible debentures, will strengthen its balance sheet and increase cash flow

TORONTO, Jan. 22, 2021 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX)(OTCQB: ENGMF)(FSE: 2AV), the largest gaming platform in North America, reaching over 300 million monthly video game and esports fans worldwide, announced that it has issued notice to the holders, of the Company’s convertible debentures (the “Debentures”) to exercise the Company’s option to convert the outstanding Debentures into common shares of the Company (the “Common Shares”). The Debentures were set to mature on December 31, 2021. Upon completion of the conversions, $9 million in principal amount of the Debentures will have been converted into approximately 2,967,163 Common Shares.

As the Company had previously announced, it has entered into an agreement with a syndicate of underwriters led by Canaccord Genuity Corp. (collectively, the “Underwriters”), pursuant to which the Underwriters have agreed to sell (the “Offering”), on a bought deal basis, up to 7,383,000 Common Shares to be issued by treasury for total gross proceeds to the Company of approximately $42.5 million (assuming exercise in full of the over-allotment option). In connection with the Offering, a selling shareholder will sell an additional 2,817,500 Common Shares (assuming exercise of the over-allotment option).

By reducing the Company’s indebtedness through the conversion of the Debentures and by raising $42.5 million upon the successful completion of the bought deal financing, the Company will have strengthened its balance sheet by more than $50 million, while reducing annual interest costs by $0.8 million.

“This week we took a major step to add a sizeable amount of growth capital, while also significantly reducing our borrowings and interest costs,”
commented Adrian Montgomery, CEO of Enthusiast Gaming.
“These two actions will strengthen our balance sheet ahead of our proposed Nasdaq listing, while we push forward with the execution of our growth strategy, which includes acquiring accretive properties which we can integrate into our platform.”

About Enthusiast Gaming

Enthusiast Gaming (TSX: EGLX)(OTCQB: ENGMF)(FSE: 2AV) is building the world’s largest social network of communities for gamers and esports fans that reaches over 300 million gaming enthusiasts on a monthly basis. Already the largest gaming platform in North America and the United Kingdom, the Company’s business is comprised of four main pillars: Esports, Content, Talent and Entertainment. Enthusiast Gaming’s esports division, Luminosity Gaming, is a leading global esports franchise that consists of 7 professional esports teams under ownership and management, including the Vancouver Titans Overwatch team and the Seattle Surge Call of Duty team. Enthusiast’s gaming content division includes 2 of the top 20 gaming media and entertainment video brands with BCC Gaming and Arcade Cloud, reaching more than 50MM unique viewers a month across 9 YouTube pages, 8 Snapchat shows and related Facebook, Instagram and TikTok accounts. Its 100 gaming-related websites including The Sims Resource, Destructoid, and The Escapist collectively generate 1.1 billion page views monthly. Enthusiast’s talent division works with nearly 1,000 YouTube creators generating nearly 3 billion views a month working with leading gamer talent such as Pokimane, Flamingo, Anomaly, and The Sidemen. Enthusiast’s entertainment business includes Canada’s largest gaming expo, EGLX (eglx.com), and the largest mobile gaming event in Europe, Pocket Gamer Connects (pgconnects.com). For more information on the Company visit enthusiastgaming.com. For more information on Luminosity Gaming visit luminosity.gg.

Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance or achievements that Enthusiast anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results “may”, “could”, “would”, “might” or “will” (or other variations of the forgoing) be taken, occur, be achieved, or come to pass. Forward-looking statements in this news release include, but are not limited to statements relating to the conversion of the Debentures, the completion of the bought deal financing, the listing of the Company on Nasdaq, the successful execution of the Company’s growth strategy, the ability to acquire accretive properties

Forward-looking statements are based on assumptions, including expectations and assumptions concerning: interest and foreign exchange rates; capital efficiencies, cost saving and synergies; growth and growth rates; the success in the esports and media industry; and the Company’s growth plan. While Enthusiast Gaming considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. In addition, forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks related risks associated with general economic conditions; adverse industry events; future legislative, tax and regulatory developments. Readers are cautioned that the foregoing list is not exhaustive and other risks set out in Enthusiast Gaming public disclosure recorded filed under the Company’s provide on www.sedar.com, including those contained in the prospectus. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. For more information on the risk, uncertainties and assumptions that could cause anticipated opportunities and actual results to differ materially, please refer to the public filings of Enthusiast Gaming which are available on SEDAR at www.sedar.com. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. Enthusiast Gaming disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts:
Enthusiast Gaming – Eric Bernofsky
Chief Corporate Officer
[email protected]

Media Relations – ID 
[email protected]

Posted on January 22, 2021 7:03 am

Updated Time: Plug Power Business Update Conference Call on January 26, 2021 to Begin at 8:30 AM ET

LATHAM, N.Y., Jan. 22, 2021 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ:PLUG), a leading provider of hydrogen engines and fueling solutions enabling e-mobility, today announced that its January 26, 2021 business update conference call will begin at a new time: 8:30 am ET. On this call, CEO, Andy Marsh, will discuss preliminary results for the full year of 2020, including continual progress versus our business goals. Additionally, Mr. Marsh will outline the company’s plans for 2021.

Join the call:

Date: January 26, 2021

New Time: 8:30 am ET

Toll-free: 877-405-1239

Direct webcast: https://event.webcasts.com/starthere.jsp?ei=1417059&tp_key=03b1210eda

The webcast can also be accessed directly from the Plug Power homepage (www.plugpower.com). A playback of the call will be available online for a period of time following the call.

About Plug Power

Plug Power is building the hydrogen economy as the leading provider of comprehensive hydrogen fuel cell (HFC) turnkey solutions. The Company’s innovative technology powers electric motors with hydrogen fuel cells amid an ongoing paradigm shift in the power, energy, and transportation industries to address climate change and energy security, while providing efficiency gains and meeting sustainability goals.

Plug Power created the first commercially viable market for hydrogen fuel cell (HFC) technology. As a result, the Company has deployed over 40,000 fuel cell systems for e-mobility, more than anyone else in the world, and has become the largest buyer of liquid hydrogen, having built and operated a hydrogen highway across North America. Plug Power delivers a significant value proposition to end-customers, including meaningful environmental benefits, efficiency gains, fast fueling, and lower operational costs. Plug Power’s vertically integrated GenKey solution ties together all critical elements to power, fuel, and provide service to customers such as Amazon, BMW, The Southern Company, Carrefour, and Walmart. The Company is now leveraging its know-how, modular product architecture and foundational customers to rapidly expand into other key markets including zero-emission on-road vehicles, robotics, and data centers.

Media Contact

Ian Martorana
The Bulleit Group
‪(415) 237-3681‬
[email protected]

Posted on January 22, 2021 7:03 am

Bank of America Announces Redemption of €2.0 Billion of Floating Rate Senior Notes, due February 7, 2022 and €1.25 Billion of 0.736% Fixed/Floating Rate Senior Notes, due February 7, 2022

Bank of America Announces Redemption of €2.0 Billion of Floating Rate Senior Notes, due February 7, 2022 and €1.25 Billion of 0.736% Fixed/Floating Rate Senior Notes, due February 7, 2022

CHARLOTTE, N.C.–(BUSINESS WIRE)–
Bank of America Corporation announced today that it will redeem on February 7, 2021 (i) all €2,000,000,000 principal amount outstanding of its Floating Rate Senior Notes, due February 7, 2022 (ISIN: XS1560862580; Common Code: 156086258) (the “Floating Rate Notes”) and (ii) all €1,250,000,000 principal amount outstanding of its 0.736% Fixed/Floating Rate Senior Notes, due February 7, 2022 (ISIN: XS1560863554; Common Code: 156086355) (the “Fixed/Floating Rate Notes” and together with the Floating Rate Notes, the “Notes”).

Each series of the Notes was issued under the Bank of America Corporation U.S.$65,000,000,000 Euro Medium-Term Note Program. The redemption price for each series of the Notes will be equal to the Optional Redemption Amount of €1,000 per €1,000 Calculation Amount (as specified in the applicable Final Terms dated February 3, 2017), plus accrued and unpaid interest to, but excluding, the redemption date of February 7, 2021. Since February 7, 2021 is not a business day, the redemption price for each series of the Notes will be paid on the next succeeding business day, February 8, 2021. Interest on each series of the Notes will cease to accrue on the redemption date.

Payment of the redemption price for each series of the Notes will be made in accordance with the applicable procedures of Euroclear Bank SA/NV and Clearstream Banking, S.A. Bank of America, N.A. (operating through its London Branch) is the Principal Agent for each series of the Notes and Bank of America Europe DAC (formerly known as Bank of America Merrill Lynch International DAC) is the Registrar for each series of the Notes.

Bank of America Corporation will request the Financial Conduct Authority to cancel the listing of each series of the Notes and the London Stock Exchange plc to cancel the admission to trading of each series of the Notes on or around the business day following the redemption date.

Bank of America

Bank of America is one of the world’s leading financial institutions, serving individual consumers, small and middle-market businesses and large corporations with a full range of banking, investing, asset management and other financial and risk management products and services. The company provides unmatched convenience in the United States, serving approximately 66 million consumer and small business clients with approximately 4,300 retail financial centers, including approximately 2,700 lending centers, 2,600 financial centers with a Consumer Investment Financial Solutions Advisor and approximately 2,400 business centers; approximately 17,000 ATMs; and award-winning digital banking with approximately 39 million active users, including approximately 31 million mobile users. Bank of America is a global leader in wealth management, corporate and investment banking and trading across a broad range of asset classes, serving corporations, governments, institutions and individuals around the world. Bank of America offers industry-leading support to approximately 3 million small business households through a suite of innovative, easy-to-use online products and services. The company serves clients through operations across the United States, its territories and approximately 35 countries. Bank of America Corporation stock (NYSE: BAC) is listed on the New York Stock Exchange.

Forward-looking statements

Certain information contained in this news release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not guarantees of future results or performance and involve certain risks, uncertainties and assumptions difficult to predict or beyond our control. You should not place undue reliance on any forward-looking statement and should consider the uncertainties and risks discussed under Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019, under Part II, Item 1A. “Risk Factors” in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020, and in any of our subsequent Securities and Exchange Commission filings. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update any forward-looking statement to reflect the impact of circumstances or events that arise after the date the forward-looking statement was made.

For more Bank of America news, including dividend announcements and other important information, visit the Bank of America newsroom. Click here to register for news email alerts.

www.bankofamerica.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210122005017/en/

Investors May Contact:

Lee McEntire, Bank of America

Phone: 1.980.388.6780

[email protected]

Jonathan G. Blum, Bank of America (Fixed Income)

Phone: 1.212.449.3112

[email protected]

Reporters May Contact:

Jerry Dubrowski, Bank of America

Phone: 1.646.855.1195 (office) or 1.508.843.5626 (mobile)

[email protected]

Christopher P. Feeney, Bank of America

Phone: 1.980.386.6794

[email protected]

KEYWORDS: United States North America North Carolina

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo